France: An unrecognized
» There is a lot of talk about the new French anti‑corruption law and whether it will have a positive impact on France’s
current inadequate enforcement of its anti‑corruption laws.
» Meanwhile, France is undergoing a “petite revolution” in relation to the transparency of the relationships between the
healthcare industry and healthcare professionals.
» The country is in the process of imposing a regime of pre‑authorization for certain types of interactions with
» We are also expecting regulations setting maximum amounts for advantages, and by type of advantages (e.g., meals,
» Finally, the country is moving toward full‑transparency mode for those interactions through more stringent rules of
There is a lot of talk about France’s new anti-corruption law dated 9 December 2016 (Sapin II Law),
including a lot of questions. However,
it all boils down to one key question: is
it going to work? Is France finally going
to join the ranks of countries
seriously enforcing their
You can read a lot of articles
inside and outside of France
referring to how French companies
might not be ready, despite the
sophistication of the pre-existing
French anti-corruption legislative
arsenal. Whether the Sapin II Law will have
a positive impact on the locally driven fight
against corruption is yet to be seen and
could take several years to play out.
The purpose of this article is not to
explore the intricacies of the Sapin II Law but
rather to highlight the ongoing revolution
in French healthcare compliance: France is
aiming toward total transparency in regard
to the interactions between the healthcare
industry and healthcare professionals.
In December 2011, France adopted the
first transparency law, called “Bertrand
Law,” in the wake of a major healthcare
scandal (the Mediator Scandal). Interpreting
the law was challenging, however, and
the pace it imposed on companies for its
implementation was simply brutal.
In a nutshell, the key milestones and
events are summarized below:
· December 2011: adoption of the
Bertrand Law, requiring a large array of
healthcare-related companies to publicly
disclose all advantages given to, and
contracts entered into, with an even
wider array of healthcare professionals.
However, the how, the what, and the
when of that public disclosure was
pretty much left up in the air.
by Cecilia Fellouse‑Guenkel, CCEP